RT @accpcardprn: Integrating CV outcomes data w/ SGLT2 inhibitor (EMPA-REG, CANVAS, etc.) and GLP-1RA trials (LEADER, etc.) has become a ho…
RT @accpcardprn: Integrating CV outcomes data w/ SGLT2 inhibitor (EMPA-REG, CANVAS, etc.) and GLP-1RA trials (LEADER, etc.) has become a ho…
RT @accpcardprn: Integrating CV outcomes data w/ SGLT2 inhibitor (EMPA-REG, CANVAS, etc.) and GLP-1RA trials (LEADER, etc.) has become a ho…
RT @accpcardprn: Integrating CV outcomes data w/ SGLT2 inhibitor (EMPA-REG, CANVAS, etc.) and GLP-1RA trials (LEADER, etc.) has become a ho…
RT @accpcardprn: Integrating CV outcomes data w/ SGLT2 inhibitor (EMPA-REG, CANVAS, etc.) and GLP-1RA trials (LEADER, etc.) has become a ho…
RT @accpcardprn: Integrating CV outcomes data w/ SGLT2 inhibitor (EMPA-REG, CANVAS, etc.) and GLP-1RA trials (LEADER, etc.) has become a ho…
RT @accpcardprn: Integrating CV outcomes data w/ SGLT2 inhibitor (EMPA-REG, CANVAS, etc.) and GLP-1RA trials (LEADER, etc.) has become a ho…
RT @accpcardprn: Integrating CV outcomes data w/ SGLT2 inhibitor (EMPA-REG, CANVAS, etc.) and GLP-1RA trials (LEADER, etc.) has become a ho…
RT @accpcardprn: Integrating CV outcomes data w/ SGLT2 inhibitor (EMPA-REG, CANVAS, etc.) and GLP-1RA trials (LEADER, etc.) has become a ho…
Integrating CV outcomes data w/ SGLT2 inhibitor (EMPA-REG, CANVAS, etc.) and GLP-1RA trials (LEADER, etc.) has become a hot topic within the cards community. Check out the 2018 ACC Decision Pathway for using these agents in DMII/ASCVD. https://t.co/N6SRPRk
RT @gonzaeperez: Consenso ACC 2018 sobre reducción de riesgo con nuevas terapias en Pac con Diabetes y enfermedad aterosclerótica Descarga…
RT @gonzaeperez: Consenso ACC 2018 sobre reducción de riesgo con nuevas terapias en Pac con Diabetes y enfermedad aterosclerótica Descarga…
RT @gonzaeperez: Consenso ACC 2018 sobre reducción de riesgo con nuevas terapias en Pac con Diabetes y enfermedad aterosclerótica Descarga…
RT @gonzaeperez: Consenso ACC 2018 sobre reducción de riesgo con nuevas terapias en Pac con Diabetes y enfermedad aterosclerótica Descarga…
RT @gonzaeperez: Consenso ACC 2018 sobre reducción de riesgo con nuevas terapias en Pac con Diabetes y enfermedad aterosclerótica Descarga…
RT @gonzaeperez: Consenso ACC 2018 sobre reducción de riesgo con nuevas terapias en Pac con Diabetes y enfermedad aterosclerótica Descarga…
RT @gonzaeperez: Consenso ACC 2018 sobre reducción de riesgo con nuevas terapias en Pac con Diabetes y enfermedad aterosclerótica Descarga…
RT @gonzaeperez: Consenso ACC 2018 sobre reducción de riesgo con nuevas terapias en Pac con Diabetes y enfermedad aterosclerótica Descarga…
RT @gonzaeperez: Consenso ACC 2018 sobre reducción de riesgo con nuevas terapias en Pac con Diabetes y enfermedad aterosclerótica Descarga…
RT @gonzaeperez: Consenso ACC 2018 sobre reducción de riesgo con nuevas terapias en Pac con Diabetes y enfermedad aterosclerótica Descarga…
RT @gonzaeperez: Consenso ACC 2018 sobre reducción de riesgo con nuevas terapias en Pac con Diabetes y enfermedad aterosclerótica Descarga…
RT @gonzaeperez: Consenso ACC 2018 sobre reducción de riesgo con nuevas terapias en Pac con Diabetes y enfermedad aterosclerótica Descarga…
RT @gonzaeperez: Consenso ACC 2018 sobre reducción de riesgo con nuevas terapias en Pac con Diabetes y enfermedad aterosclerótica Descarga…
Consenso ACC 2018 sobre reducción de riesgo con nuevas terapias en Pac con Diabetes y enfermedad aterosclerótica Descarga gratuita @JACCJournals #Diabetes https://t.co/VDnZVQ7IJg https://t.co/eZZi2CLqbA
RT @JACCJournals: @ACCinTouch releases Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients With Type 2 #…
Can you cut the risk? 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease https://t.co/vQteM0ahnm
Important consensus statement highlighting the use of two new exciting classes of drugs (SGLT2 inhibitors and GLP-1 Agonists) that lower CV events in patients with type 2 diabetes: https://t.co/o9S8WpP7Q1
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @acorderofort: 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
ACC offers advice for CV risk reduction in patients with type 2 diabetes, according to @JACCJournals https://t.co/Ba55DAoeks https://t.co/TvxDV4ZRk6
RT @HCSgr: Εκτίμηση και αντιμετώπιση του ΣΔ2 σε ασθενείς με καρδιαγγειακές παθήσεις. https://t.co/DMg1PoPkD3... https://t.co/DMg1PoPkD3
RT @HCSgr: Εκτίμηση και αντιμετώπιση του ΣΔ2 σε ασθενείς με καρδιαγγειακές παθήσεις. https://t.co/DMg1PoPkD3... https://t.co/DMg1PoPkD3
Εκτίμηση και αντιμετώπιση του ΣΔ2 σε ασθενείς με καρδιαγγειακές παθήσεις. https://t.co/DMg1PoPkD3... https://t.co/DMg1PoPkD3
GLP-1 and SGLT-2 inhibitors and CV benefit. Care pathway from the ACC/AHA. https://t.co/HblJIhBvR4
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
2018 ACC Expert Consensus Decision Pathway on Novel Therapies (#SGLT2-i and #GLP1-ra) for CVR reduction in pts w #T2D and ASCVD. via @JACCJournals https://t.co/A9BzjQP1hK https://t.co/CjTnw7CaEF
2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With T2DM and ASCVD. https://t.co/lUt9IVD6Ar … from @sandeepdasmd @_brendan_ & @JJheart_doc et al. https://t.co/WkGJEnckSr
RT @JACCJournals: @ACCinTouch releases Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients With Type 2 #…
2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease https://t.co/vWTgNFC1hM … https://t.co/tY7Xx0Cc01 https://t.co/3wlfzWQF0W
RT @DanielJDrucker: 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2…
2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease https://t.co/s3yK3yCXfF
RT @DanielJDrucker: 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2…
RT @DanielJDrucker: 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2…
RT @JORARTU: 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabet…
My light reading over the weekend ... 🤓❤️ https://t.co/kp1wcfJvpA
RT @JORARTU: 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabet…
2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease | JACC: Journal of the American College of Cardiology https://t.co/ZLbtkYzehu
Cardiologists, we need to weigh in on DM2 management and recommend SGLT2 inhibitors ("flozins") and GLP-1RA ("tides") when appropriate. Read this report --> https://t.co/UoDKyXtkRH
RT @JACCJournals: @ACCinTouch releases Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients With Type 2 #…
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @DiegoBellido2: 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2…
RT @JACCJournals: @ACCinTouch releases Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients With Type 2 #…
RT @JACCJournals: @ACCinTouch releases Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients With Type 2 #…
RT @JACCJournals: @ACCinTouch releases Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients With Type 2 #…
RT @JACCJournals: @ACCinTouch releases Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients With Type 2 #…
RT @ATRIUMRx: Per the 2018 ACC Expert Consensus Decision Pathway, if SGLT2 inhibitor is selected, empagliflozin is preferred. If GLP-1RA is…
RT @JACCJournals: @ACCinTouch releases Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients With Type 2 #…
RT @JACCJournals: @ACCinTouch releases Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients With Type 2 #…
RT @JACCJournals: @ACCinTouch releases Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients With Type 2 #…
RT @JACCJournals: @ACCinTouch releases Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients With Type 2 #…
RT @JJheart_doc: An important Expert Consensus document from the ACC. Cardiologists must learn novel diabetes therapies for optimal manage…
RT @ATRIUMRx "ACC has published a consensus decision on novel diabetes medications for patients with T2DM and CV disease! Check out their recommendations for SGLT-2 inhibitors and GLP-1RAs for this patient population #cardioed #foamed https://t.co/UnWEvppn
RT @ATRIUMRx: Per the 2018 ACC Expert Consensus Decision Pathway, if SGLT2 inhibitor is selected, empagliflozin is preferred. If GLP-1RA is…
RT @ATRIUMRx: Per the 2018 ACC Expert Consensus Decision Pathway, if SGLT2 inhibitor is selected, empagliflozin is preferred. If GLP-1RA is…
Per the 2018 ACC Expert Consensus Decision Pathway, if SGLT2 inhibitor is selected, empagliflozin is preferred. If GLP-1RA is selected, liraglutide is the preferred agent. What do you think of these recommendations? #cardioed #FOAMed https://t.co/i6sjrANy4
RT @JACCJournals: @ACCinTouch releases Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients With Type 2 #…
RT @JACCJournals: @ACCinTouch releases Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients With Type 2 #…
@ACCinTouch releases Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients With Type 2 #Diabetes and Atherosclerotic CVD, including newer SGLT-2 and GLP-1RA agents: https://t.co/IqGWwQQARo https://t.co/KONgLZ4xX1
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @ADA_DiabetesPro: We endorse @ACCinTouch's new 2018 Expert Consensus Decision Pathway, which addresses the changing paradigm in how card…
RT @DiegoBellido2: 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2…
RT @JJheart_doc: An important Expert Consensus document from the ACC. Cardiologists must learn novel diabetes therapies for optimal manage…
(JACC) Consenso del ACC sobre los nuevos ttos para didminuir el riesgo CV en pacientes con DM2 en prevención 2ª. https://t.co/6YBXslSrXA
RT @AArmbruster09: Great guidance for patients with ASCVD and diabetes! https://t.co/DshAS7VEKg https://t.co/TcSm1Kvaiz
RT @JJheart_doc: An important Expert Consensus document from the ACC. Cardiologists must learn novel diabetes therapies for optimal manage…
RT @JJheart_doc: An important Expert Consensus document from the ACC. Cardiologists must learn novel diabetes therapies for optimal manage…
RT @ATRIUMRx: ACC has published a consensus decision on novel diabetes medications for patients with T2DM and CV disease! Check out their r…
RT @AArmbruster09: Great guidance for patients with ASCVD and diabetes! https://t.co/DshAS7VEKg https://t.co/TcSm1Kvaiz
RT @Cardio_delaGuia: Consenso #ACC sobre nuevos fármacos #diabetes y efectos CV. Analizan 2 inhibidores SGLT2 (empa y canagliflozina) y 4 G…
Great guidance for patients with ASCVD and diabetes! https://t.co/DshAS7VEKg https://t.co/TcSm1Kvaiz
RT @SantasEnrique: DM 2 con enf CV establecida ➡️ control global FRCV (STENO-2) + iSGLT2/GLP-1; preferencia para empaglifozina y liraglutid…
2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. https://t.co/jPstbiic19 …https://t.co/2Vl2xquQoG https://t.co/D833T0EHp0 https://t.
RT @ATRIUMRx: New ACC consensus decision pathway for novel diabetes medications for patients with clinical ASCVD recommend initiating a pat…
RT @ATRIUMRx: New ACC consensus decision pathway for novel diabetes medications for patients with clinical ASCVD recommend initiating a pat…
New ACC consensus decision pathway for novel diabetes medications for patients with clinical ASCVD recommend initiating a patient/clinician discussion on adding a SGLT2 inhibitor or GLP-1RA with demonstrated CV benefit #cardioed #foamed https://t.co/i6sjrA
RT @FarmaMadridAP: (JACC) Consenso de expertos de ACC 2018 sobre nuevas terapias para la reducción del riesgo cardiovascular en pacientes c…
RT @DiegoBellido2: 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2…
Casi coincidiendo con el documento de ESC,publicado en JACC nuevo documento consenso en DM https://t.co/3K3LOl6j9D
RT @ATRIUMRx: ACC has published a consensus decision on novel diabetes medications for patients with T2DM and CV disease! Check out their r…
RT @ATRIUMRx: ACC has published a consensus decision on novel diabetes medications for patients with T2DM and CV disease! Check out their r…